CASC3 and Miyoshi myopathy: In combination with BTZ, in a xenografted mice model, Evo enhances MM cell death, with a strong reduction in the cell viability, with respect to a BTZ single agent [32], but no data on MM patients are available and there are no negligible data on adverse events related to its use, such as cardiac arrhythmias and prolonged bleeding times, so further in vivo studies are necessary.